<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7073089/results/search/test_trace/results.xml">
  <result pre="is particularly difficult to treat because HCMV has a life-long" exact="infection" post="in its hosts, high mutation rate, and latent infections."/>
  <result pre="investigated to remove acute and/or latent CMV infections. For the" exact="treatment" post="of glioblastoma, vaccine therapy through targeting specific CMV antigens"/>
  <result pre="new virions. CMV express lytic genes to demonstrate a symptomatic" exact="infection" post="in hosts [24]. Alternatively, CMV may go into a"/>
  <result pre="long-term latency in hosts is usually asymptomatic, though the primary" exact="infection" post="is not necessarily asymptomatic. When CMV are stimulated by"/>
  <result pre="Infection Because CMV can be transmitted by the close interpersonal" exact="contact" post="such as saliva, semen, urine, breast milk, or vertical"/>
  <result pre="the fetus) [28,29] which is the leading cause of congenital" exact="infection" post="[30,31,32,33]. Congenital CMV infection is both inherent infection and"/>
  <result pre="is the leading cause of congenital infection [30,31,32,33]. Congenital CMV" exact="infection" post="is both inherent infection and intrauterine infection [34,35]. Intrauterine"/>
  <result pre="of congenital infection [30,31,32,33]. Congenital CMV infection is both inherent" exact="infection" post="and intrauterine infection [34,35]. Intrauterine transmission may occur in"/>
  <result pre="[30,31,32,33]. Congenital CMV infection is both inherent infection and intrauterine" exact="infection" post="[34,35]. Intrauterine transmission may occur in mothers without immune"/>
  <result pre="either by the reactivation of previous infections or by the" exact="infection" post="of a different viral strain (non-primary infection) [36]. A"/>
  <result pre="transmit viruses to a neonate if she is undergoing primary" exact="infection" post="or robust reactivation. Most of congenital infections are asymptomatic"/>
  <result pre="(10–15%), but the symptomatic disease usually emerges after primary maternal" exact="infection" post="in pregnancy [37,38]. The morbidity risk in newborns is"/>
  <result pre="loss in hearing, and impairment in eyesight. 2.2. Sequelaes CMV" exact="infection" post="is mostly asymptomatic among the general population; however, around"/>
  <result pre="impairment [43,44,45]. This means the asymptomatic newborns with congenital CMV" exact="infection" post="still have an increased risk for long-term sequelae, especially,"/>
  <result pre="urine may be useful for evaluating the response for the" exact="treatment" post="and clinical outcomes [51]. Congenital CMV infections can lead"/>
  <result pre="ganciclovir remains to be the first line drug for the" exact="treatment" post="of CMV infections. Ganciclovir and valganciclovir are mainly used"/>
  <result pre="5 years. Valnoctamide, a neuroactive mood stabilizer which inhibits CMV" exact="infection" post="in developing brain and attenuates neurobehavioral dysfunctions, was shown"/>
  <result pre="(letermovir, maribavir, and brincidofovir) are also potentially applied for the" exact="treatment" post="of brain disease associated with CMV infections. 3.1. Letermovir"/>
  <result pre="[63]. It has been clinically applied for CMV prophylaxis or" exact="treatment" post="in hematopoietic stem cell recipients, thoracic organ recipients and"/>
  <result pre="toxicity for kidney and bone marrow, the breakthrough of CMV" exact="treatment" post="with letermovir is that it targets the CMV terminase"/>
  <result pre="Consequently, letermovir is also promising to be used in the" exact="treatment" post="of brain diseases associated with CMV infections. 3.2. Maribavir"/>
  <result pre="is an experimental antiviral CMV drug being developed for the" exact="treatment" post="of CMV, adenovirus, smallpox, and ebolavirus infections [72]. Marty"/>
  <result pre="phase III trial for the prevention of clinically significant CMV" exact="infection" post="in allogeneic HCT recipients. However, the results showed that"/>
  <result pre="The patients with GBM seldom survived five years beyond initial" exact="diagnosis" post="and their prognosis is poor despite surgical resection, high-dose"/>
  <result pre="proteins immediately early protein-1 and pp65 [88,89,90,91]. The currently standard" exact="treatment" post="does not significantly improve the clinical outcomes; thus, it"/>
  <result pre="and efficacy using CMV-specific vaccine therapy and immunotherapy for the" exact="treatment" post="of GBM. Acknowledgments We are grateful for the grant"/>
  <result pre="of glioblastomaJ. Neuro-Oncol.2012108112710.1007/s11060-011-0793-0 13.YoungR.M.JamshidiA.DavisG.ShermanJ.H.Current trends in the surgical management and" exact="treatment" post="of adult glioblastomaAnn. Transl. Med.2015312110.3978/j.issn.2305-5839.2015.05.1026207249 14.GallegoO.Nonsurgical treatment of recurrent"/>
  <result pre="surgical management and treatment of adult glioblastomaAnn. Transl. Med.2015312110.3978/j.issn.2305-5839.2015.05.1026207249 14.GallegoO.Nonsurgical" exact="treatment" post="of recurrent glioblastomaCurr. Oncol.201522e27310.3747/co.22.243626300678 15.Adult Brain Tumors Treatment. National"/>
  <result pre="22.MarschallM.FreitagM.WeilerS.SorgG.StammingerT.Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for" exact="screening" post="antiviral agentsAntimicrob Agents Chemother.2000441588159710.1128/AAC.44.6.1588-1597.200010817714 23.MelnickM.SedghizadehP.P.AllenC.M.JaskollT.Human cytomegalovirus and mucoepidermoid carcinoma"/>
  <result pre="highly cytomegalovirus-immune maternal populationAm. J. Obstet. Gynecol.2010202297.e1297.e810.1016/j.ajog.2009.11.01820060091 30.StarasS.A.DollardS.C.RadfordK.W.FlandersW.D.PassR.F.CannonM.J.Seroprevalence of cytomegalovirus" exact="infection" post="in the United States, 1988–1994Clin. Infect. Dis.2006431143115110.1086/50817317029132 31.HargettD.ShenkT.E.Experimental human"/>
  <result pre="CD14+ monocytesProc. Natl. Acad. Sci. USA2010107200392004410.1073/pnas.101450910721041645 32.DollardS.C.GrosseS.D.RossD.S.New estimates of the" exact="prevalence" post="of neurological and sensory sequelae and mortality associated with"/>
  <result pre="congenital cytomegalovirus (CMV) infectionRev. Med Virol.20071725327610.1002/rmv.53517579921 34.LazzarottoT.GuerraB.GabrielliL.LanariM.LandiniM.P.Update on the prevention," exact="diagnosis" post="and management of cytomegalovirus infection during pregnancyClin. Microbiol. Infect2011171285129310.1111/j.1469-0691.2011.03564.x21631642"/>
  <result pre="Virol.20071725327610.1002/rmv.53517579921 34.LazzarottoT.GuerraB.GabrielliL.LanariM.LandiniM.P.Update on the prevention, diagnosis and management of cytomegalovirus" exact="infection" post="during pregnancyClin. Microbiol. Infect2011171285129310.1111/j.1469-0691.2011.03564.x21631642 35.PiconeO.Vauloup-FellousC.CordierA.G.GuittonS.SenatM.V.FuchsF.AyoubiJ.M.Grangeot KerosL.BenachiA.A series of 238"/>
  <result pre="infection: New prospects for prevention and therapyPediatric Clin.20136033534910.1016/j.pcl.2012.12.008 43.YamamotoA.Y.Mussi-PinhataM.M.IsaacM.D.AmaralF.R.CarvalheiroC.G.AragonD.C.ManfrediA.K.BoppanaS.B.BrittW.J.Congenital cytomegalovirus" exact="infection" post="as a cause of sensorineural hearing loss in a"/>
  <result pre="a highly immune populationPediatric Infect. Dis. J.201130104310.1097/INF.0b013e31822d964021814153 44.FowlerK.B.BoppanaS.B.Congenital cytomegalovirus (CMV)" exact="infection" post="and hearing deficitJ. Clin. Virol.20063522623110.1016/j.jcv.2005.09.01616386462 45.BoppanaS.B.RossS.A.FowlerK.B.Congenital cytomegalovirus infection: Clinical"/>
  <result pre="45.BoppanaS.B.RossS.A.FowlerK.B.Congenital cytomegalovirus infection: Clinical outcomeClin. Infect. Dis.201357S178S18110.1093/cid/cit62924257422 46.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth" exact="prevalence" post="and natural history of congenital cytomegalovirus infection in a"/>
  <result pre="46.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth prevalence and natural history of congenital cytomegalovirus" exact="infection" post="in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 47.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus"/>
  <result pre="infection in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 47.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus" exact="infection" post="following first trimester maternal infection: Symptoms at birth and"/>
  <result pre="block of MHC class I antigen presentationFront. Immunol.201910177610.3389/fimmu.2019.0177631417555 53.CobbsC.S.HsiehL.SamantaM.GillespieG.Y.BhararaS.KingP.H.NaborsL.B.CobbsC.G.BrittW.J.Human cytomegalovirus" exact="infection" post="and expression in human malignant gliomaCancer Res.2002623347335012067971 54.McFaline-FigueroaJ.R.WenP.Y.The viral"/>
  <result pre="Attenuates Neurobehavioral Dysfunctions and Brain AbnormalitiesJ. Neurosci.2017376877689310.1523/JNEUROSCI.0970-17.201728630251 62.KrishnaB.A.WillsM.R.SinclairJ.H.Advances in the" exact="treatment" post="of cytomegalovirusBr. Med. Bull.201913151710.1093/bmb/ldz03131580403 63.PoppingS.DalmV.A.LübkeN.CristanzianoV.D.KaiserR.BoucherC.A.Van KampenJ.J.Emergence and persistence of"/>
  <result pre="al.Single-center experience with use of letermovir for CMV prophylaxis or" exact="treatment" post="in thoracic organ transplant recipientsTranspl. Infect. Dis.2019e1316610.1111/tid.1316631487755 66.VeitT.MunkerD.KaukeT.ZollerM.MichelS.CeelenF.SchiopuS.BartonJ.ArnoldP.MilgerK.et al.Letermovir"/>
  <result pre="recipientsTranspl. Infect. Dis.2019e1316610.1111/tid.1316631487755 66.VeitT.MunkerD.KaukeT.ZollerM.MichelS.CeelenF.SchiopuS.BartonJ.ArnoldP.MilgerK.et al.Letermovir for difficult to treat cytomegalovirus" exact="infection" post="in lung transplant recipientsTransplantation201910.1097/TP.000000000000288631385924 67.ChemalyR.F.UllmannA.J.StoelbenS.RichardM.P.BornhäuserM.GrothC.EinseleH.SilvermanM.MullaneK.M.BrownJ.et al.Letermovir for cytomegalovirus prophylaxis"/>
  <result pre="cytomegalovirus in hematopoietic-cell transplantationN. Engl. J. Med.20173772433244410.1056/NEJMoa170664029211658 69.MaertensJ.CordonnierC.JakschP.PoiréX.UknisM.WuJ.WijatykA.SalibaF.WitzkeO.VillanoS.Maribavir for preemptive" exact="treatment" post="of cytomegalovirus reactivationN. Engl. J. Med.20193811136114710.1056/NEJMoa171465631532960 70.PapanicolaouG.A.SilveiraF.P.LangstonA.A.PereiraM.R.AveryR.K.UknisM.WijatykA.WuJ.BoeckhM.MartyF.M.et al.Maribavir for"/>
  <result pre="TherapyCurr. Hematol. Malig. Rep.202010.1007/s11899-020-00557-6 72.LanierR.TrostL.TippinT.LampertB.RobertsonA.FosterS.RoseM.PainterW.O’MahonyR.AlmondM.et al.Development of CMX001 for the" exact="treatment" post="of poxvirus infectionsViruses201022740276210.3390/v212274021499452 73.MartyF.M.WinstonD.J.ChemalyR.F.MullaneK.M.ShoreT.B.PapanicolaouG.A.ChittickG.BrundageT.M.WilsonC.MorrisonM.E.et al.A randomized, double-blind, placebo-controlled phase"/>
  <result pre="Trans. R. Soc. B Biol. Sci.20113662936294110.1098/rstb.2011.0142 77.LiW.ShengJ.XuM.VuG.P.YangZ.LiuY.SunX.TrangP.LuS.LiuF.Inhibition of murine cytomegalovirus" exact="infection" post="in animals by RNase P-associated external guide sequencesMol. Ther."/>
  <result pre="Nucleic Acids20171532233210.1016/j.omtn.2017.10.00729246310 78.LiW.LiuY.WangY.LiR.TrangP.TangW.YangZ.WangY.SunX.XingX.et al.Engineered RNase P ribozymes effectively inhibit the" exact="infection" post="of murine cytomegalovirus in animalsTheranostics201885634564410.7150/thno.2777630555569 79.DengQ.LiuY.LiX.YanB.SunX.TangW.TrangP.YangZ.GongH.WangY.et al.Inhibition of human"/>
  <result pre="birth, malnutrition, exposure to certain diseases or toxins, cytomegalovirus (CMV)" exact="infection" post="Largely unclear, maybe genetics, radiation, CMV infection Main symptom"/>
  <result pre="toxins, cytomegalovirus (CMV) infection Largely unclear, maybe genetics, radiation, CMV" exact="infection" post="Main symptom Vomiting, nausea, speech difficulty, ear bleeding, numbness,"/>
  <result pre="difficulty, imbalance, change in hearing, speech or vision [13,14,15] Clinical" exact="treatment" post="Medication, physical therapy, language therapy, psychiatry, surgery [1,2] Medication,"/>
 </snippets>
</snippetsTree>
